With the investment, Beacon will set itself up to accelerate neurobiomarker discovery and broaden clinical adoption.
Key takeaways:
- The oversubscribed $86 million Series B brings Beacon’s total funding to more than $121 million.
- Beacon’s Waveband device captures real-world sleep and wake EEG at home, feeding a foundation model trained on millions of hours of data.
- The Beacon Platform generates AI-derived biomarkers intended to support diagnosis, patient selection, and CNS drug development.
- Investors include Innoviva, Google Ventures, Nexus NeuroTech Ventures, S32, Catalio, and Takeda, with continued backing from General Catalyst and others.
- Beacon recently integrated CleveMed’s home sleep testing technology to add airflow, respiratory effort, and oximetry to its dataset.
Beacon Biosignals recently closed an oversubscribed $86 million Series B to build a large neurodiagnostic dataset and advance the clinical application of artificial intelligence (AI)-driven biomarkers for brain health.
The round was backed by healthcare and technology investors, including Innoviva, Google Ventures, Nexus NeuroTech Ventures, S32, Catalio Capital Management, and Takeda, with continued support from General Catalyst, Logos Capital, Casdin Capital, and Indicator Ventures. This financing brings Beacon’s total funding to more than $121 million.
Beacon’s FDA-cleared Waveband measures the brain’s electrical activity during sleep and wake, bringing EEG into patients’ homes. The resulting biosignal data provide longitudinal measures of brain function across diverse populations. It fuels Beacon’s foundation model of brain activity, trained on millions of hours of EEG to uncover early disease signatures and predict treatment response.
“Our mission is to make brain function measurable and actionable at scale,” says Jacob Donoghue, MD, PhD, CEO and co-founder of Beacon Biosignals, in a release. “By training AI on millions of hours of real-world brain data, we’re beginning to map the signals of health and disease in ways that can accelerate drug development and ultimately improve how patients are diagnosed and treated.”
With this new investment, Beacon is scaling its technology and operations to accelerate neurobiomarker discovery and broaden clinical adoption. The company’s core technology, the Beacon Platform, unites large-scale EEG data with AI to generate objective, quantitative biomarkers of brain function through sleep—an underutilized window into brain health, serving as both a key symptom and a mechanistic pathway across conditions such as clinical depression, Parkinson’s disease, Alzheimer’s disease, and sleep apnea.
Beacon’s research and development collaborations with biopharmaceutical companies and biotechs leverage AI-derived biomarkers to accelerate central nervous system drug development and commercialization, providing quantitative clinical endpoints, enabling more precise patient selection, and helping close care gaps in neurological and psychiatric disease. Current named partners include companies such as Takeda, UCB, and Syndeio.
The Series B follows Beacon’s recent acquisition and integration of CleveMed’s home sleep testing technology, expanding the Beacon Platform beyond EEG to include airflow, respiratory effort, and oxygen saturation.
“For too long, neurology and psychiatry have lacked the kind of objective biomarkers that revolutionized other areas of medicine,” says Anthony Philippakis, MD, PhD, general partner at Google Ventures. “Beacon’s ability to translate real-world sleep EEG into actionable insights brings that same precision to brain health, enabling more targeted, data-driven treatment development.”
“We’re thrilled to partner with Beacon as they build the infrastructure for precision neuroscience,” says Pavel Raifeld, CEO of Innoviva, in a release. “By connecting real-world brain data to both drug development and clinical care, Beacon is building a category-defining business positioned for sustained growth and broad impact in [central nervous system] therapeutics.”
